JP2014501284A - Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 - Google Patents

Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 Download PDF

Info

Publication number
JP2014501284A
JP2014501284A JP2013547684A JP2013547684A JP2014501284A JP 2014501284 A JP2014501284 A JP 2014501284A JP 2013547684 A JP2013547684 A JP 2013547684A JP 2013547684 A JP2013547684 A JP 2013547684A JP 2014501284 A JP2014501284 A JP 2014501284A
Authority
JP
Japan
Prior art keywords
composition
concentration
weight
composition according
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013547684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501284A5 (enExample
Inventor
エリック ティー． フォッセル，
Original Assignee
ストラテジック サイエンス アンド テクノロジーズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ストラテジック サイエンス アンド テクノロジーズ， エルエルシー filed Critical ストラテジック サイエンス アンド テクノロジーズ， エルエルシー
Publication of JP2014501284A publication Critical patent/JP2014501284A/ja
Publication of JP2014501284A5 publication Critical patent/JP2014501284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013547684A 2010-12-29 2011-12-29 Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 Pending JP2014501284A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061428213P 2010-12-29 2010-12-29
US201061428057P 2010-12-29 2010-12-29
US61/428,213 2010-12-29
US61/428,057 2010-12-29
PCT/US2011/067990 WO2012092525A1 (en) 2010-12-29 2011-12-29 Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015239307A Division JP2016033168A (ja) 2010-12-29 2015-12-08 Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法

Publications (2)

Publication Number Publication Date
JP2014501284A true JP2014501284A (ja) 2014-01-20
JP2014501284A5 JP2014501284A5 (enExample) 2015-02-19

Family

ID=46383540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013547684A Pending JP2014501284A (ja) 2010-12-29 2011-12-29 Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
JP2015239307A Pending JP2016033168A (ja) 2010-12-29 2015-12-08 Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015239307A Pending JP2016033168A (ja) 2010-12-29 2015-12-08 Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法

Country Status (5)

Country Link
US (1) US20140004177A1 (enExample)
EP (1) EP2658553A4 (enExample)
JP (2) JP2014501284A (enExample)
CN (1) CN103442722A (enExample)
WO (1) WO2012092525A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510354A (ja) * 2020-01-10 2023-03-13 ブリオリ バイオテック，エルエルシー ロフェコキシブを含有する外用組成物並びにそれを製造及び使用する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
AU2005235308B2 (en) * 2004-04-19 2011-12-01 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
WO2010151240A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
DK2658551T3 (da) 2010-12-29 2020-09-21 Strategic Science & Tech Llc Behandling af erektil dysfunktion og andre indikationer
CN105878172A (zh) 2010-12-29 2016-08-24 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
WO2014152280A1 (en) * 2013-03-15 2014-09-25 Strategic Science & Technologies, Llc Transdermal formulations of fluticasone
WO2016112201A1 (en) * 2015-01-07 2016-07-14 Strategic Science & Technologies, Llc Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
US12440438B2 (en) * 2019-07-22 2025-10-14 Novilla Pharmaceuticals, Inc. Method of remotely controlling pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532696A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 不利な生物物理学的環境によりもたらされる有益な物質の経皮送達
WO2010045415A2 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical nsaid compositions having sensate component

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
CA2823407C (en) * 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2010151240A1 (en) * 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532696A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 不利な生物物理学的環境によりもたらされる有益な物質の経皮送達
WO2010045415A2 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical nsaid compositions having sensate component

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510354A (ja) * 2020-01-10 2023-03-13 ブリオリ バイオテック，エルエルシー ロフェコキシブを含有する外用組成物並びにそれを製造及び使用する方法

Also Published As

Publication number Publication date
EP2658553A4 (en) 2015-01-07
WO2012092525A1 (en) 2012-07-05
JP2016033168A (ja) 2016-03-10
US20140004177A1 (en) 2014-01-02
CN103442722A (zh) 2013-12-11
EP2658553A1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
JP7187522B2 (ja) 勃起不全および他の適応症の処置
JP2016033168A (ja) Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
US9161915B2 (en) Delivery of ibuprofen and other compounds
JP2014501286A (ja) 真菌感染症および他の適応症に対する処置の経皮的送達
JP2016153434A (ja) 片頭痛および他の適応症の処置のための方法およびシステム
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
CN105307635A (zh) 西地那非和其他5型磷酸二酯酶抑制剂的透皮递送
JP2016513686A (ja) フルチカゾンの経皮製剤
JP2025183462A (ja) 勃起不全および他の適応症の処置
HK40039061B (en) Treatment of erectile dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170223